There is no standard method for measuring costs of vision impairment. Examples are given of global estimates and from two industrialized countries, Australia and the USA. The comparisons between these countries illustrate how the differences in healthcare systems influence the contribution of direct and indirect costs to the total. Modeling of costs and outcomes (cost-effectiveness analysis) has illustrated the extraordinary benefit of programs to prevent vision loss and blindness. These data need to be used in advocacy for the funding of national Vision 2020: the Right to Sight programs.
No takes yet. Share an insight, caveat, or question.
Jill Keeffe (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: